egfr/cd3-targeting t-cell engaging molecule tak-186
Generic: EGFR/CD3-targeting T-cell Engaging Molecule TAK-186
egfr/cd3-targeting t-cell engaging molecule tak-186: 1 clinical trial tracked.
egfr/cd3-targeting t-cell engaging molecule tak-186 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about egfr/cd3-targeting t-cell engaging molecule tak-186, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (1)
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-186 (Also Known as MVC-101), An EGFR x CD3 COnditional Bispecific Redirected Activation (COBRA) Protein in Patients With Unresectable Locally Advanced or Metastatic Cancer
Primary endpoint: Number of Participants with Treatment Emergent Adverse Events (TEAEs)
Interventionalopen95 targetStarted 2021-03Completion 2025-0627 sites · Australia, South Korea, United Kingdom, United StatesTakeda